Jiawen Qian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8994743/publications.pdf

Version: 2024-02-01

		1040056	1125743
13	503	9	13
papers	citations	h-index	g-index
14	14	14	968
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The IFN- \hat{I}^3 /PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. Journal of Neuroinflammation, 2018, 15, 290.	7.2	177
2	MiRâ€15a/16 deficiency enhances antiâ€tumor immunity of gliomaâ€infiltrating CD8+ T cells through targeting mTOR. International Journal of Cancer, 2017, 141, 2082-2092.	5.1	67
3	Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial. Cancer Immunology, Immunotherapy, 2018, 67, 1777-1788.	4.2	67
4	TLR2 Promotes Glioma Immune Evasion by Downregulating MHC Class II Molecules in Microglia. Cancer Immunology Research, 2018, 6, 1220-1233.	3.4	64
5	TLR1/TLR2 signaling blocks the suppression of monocytic myeloid-derived suppressor cell by promoting its differentiation into M1-type macrophage. Molecular Immunology, 2019, 112, 266-273.	2.2	32
6	Systemic injection of TLR1/2 agonist improves adoptive antigen-specific T cell therapy in glioma-bearing mice. Clinical Immunology, 2014, 154, 26-36.	3.2	25
7	MicroRNA 15a/16â€1 suppresses aryl hydrocarbon receptor–dependent interleukinâ€22 secretion in CD4+ T cells and contributes to immuneâ€mediated organ injury. Hepatology, 2018, 67, 1027-1040.	7.3	22
8	Fcµ Receptor Promotes the Survival and Activation of Marginal Zone B Cells and Protects Mice against Bacterial Sepsis. Frontiers in Immunology, 2018, 9, 160.	4.8	13
9	Identification and immunological evaluation of novel TLR2 agonists through structure optimization of Pam3CSK4. Bioorganic and Medicinal Chemistry, 2019, 27, 2784-2800.	3.0	12
10	Biological Response Modifier in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2016, 909, 69-138.	1.6	8
11	Low percentage of CD24hiCD27+CD19+ B cells decelerates gastric cancer progression in XELOX-treated patients. International Immunopharmacology, 2015, 26, 322-327.	3.8	7
12	Advances in Brain Delivery Systems Based on Biomimetic Nanoparticles. ChemNanoMat, 2022, 8, .	2.8	4
13	Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor. Cancer Immunology, Immunotherapy, 2022, 71, 2801-2814.	4.2	3